A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Eisai Inc.
Hoffmann-La Roche
Nuvectis Pharma, Inc.
AstraZeneca
Eli Lilly and Company
AstraZeneca
Maia Biotechnology
Plexium, Inc.
Maia Biotechnology
EMD Serono
Delfi Diagnostics Inc.
TScan Therapeutics, Inc.
Rondo Therapeutics
Bristol-Myers Squibb
Immuneering Corporation
Paradigm Health
Novartis
Turning Point Therapeutics, Inc.
Hoffmann-La Roche
Immuneering Corporation
Creative Biosciences (Guangzhou) Co., Ltd.
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Carisma Therapeutics Inc
Nimbus Therapeutics
Merck Sharp & Dohme LLC
Pfizer
Advaxis, Inc.
AO GENERIUM
Mural Oncology, Inc
Adaptimmune
Blueprint Medicines Corporation
Novartis
Checkpoint Therapeutics, Inc.
Novartis
Elevation Oncology
Takeda
Endocyte
Endocyte
Acrotech Biopharma Inc.
Boehringer Ingelheim
ValiSeek Limited
Sunesis Pharmaceuticals
Celgene
Berry Genomics Co., Ltd.
Boehringer Ingelheim
Takeda
Merck Sharp & Dohme LLC
Santa Maria Biotherapeutics
Imunon